Clinical trials: Prostate Cancer (Adenocarcinoma)
Metastatic Prostate Adenocarcinoma
Evaluation of PSMA Antagonist Produced by Two Different Methods
Patients with metastatic prostate cancer will undergo two protocol 68Ga-PET scans within 24-48 hours with 68Ga-PSMA-cyclotron and 68Ga-PSMA-generator radiotracers.
- Trial name
- NCT04685811
- Testing
- 68Ga-PSMA-generator vs. 68Ga-PSMA-cyclotron
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Weill Medical College of Cornell University
Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer
The purpose of this research study is to find out if a new anti-cancer drug, dasatinib (Sprycel®), previously approved for treatment of some forms of leukemia, will be safe and helpful in treating patients with hormone-refractory…
- Conditions
- Hormone-refractory Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Prostate Cancer
- Trial name
- NCT00570700
- Testing
- Dasatinib
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of California, Irvine
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS)
- Trial name
- NCT03549000
- Testing
- NZV930, PDR001, NIR178
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma of the Prostate
Muscadine Plus (MPX) In Men With Prostate Cancer
This research is being done to determine if men with rising PSA after initial therapy for localized prostate cancer who display the Alanine/Alanine SOD2 genotype of MnSOD and supplement their diet with MPX have greater decrease…
- Trial name
- NCT03535675
- Testing
- Muscadine Plus
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Adenocarcinoma of Prostate
HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.
Investigators compare in a randomized clinical trial the results and side effects of high-dose- and low-dose-rate brachytherapy as monotherapy in the treatment of early, organ confined prostate cancer patients.
- Trial name
- PROMOBRA (NCT02258087)
- Testing
- LDR Brachytherapy, HDR Brachytherapy
- Where
- Hungary
- Volunteers
- 50 people
- Sponsor
- National Institute of Oncology, Hungary
Prostate Cancer (Adenocarcinoma), Localized Prostate Cancer
68Ga-PSMA-11 PET/MRI for Selecting Men With Prostate Cancer for Focal Therapy
Focal therapy is a minimally invasive treatment option for some men with localized prostate cancer. Unlike surgery or radiation, focal therapy treats only the area of the prostate containing clinically significant cancer, with…
- Trial name
- PSMA-FT (NCT07747493)
- Testing
- Gallium Ga 68 Gozetotide (68Ga-PSMA-11), Intervention Description: Integrated positron emission tomography/magnetic resonance imaging (PET/MRI) combines molecular imaging with high-resolution anatomical MRI to evaluate intraprostatic lesions
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Blood Pressure, Hypertension
Onco-primary Care Networking to Support TEAM-based Care
The proposed ONE TEAM Study is an 18-month, cluster randomized controlled trial. This study will use a sequential multiple assignment randomized trial (SMART) design with a second randomization for the intervention group using a…
- Conditions
- Blood Pressure, Hypertension, Cancer, Cancer, Breast
- Trial name
- ONE TEAM (NCT04258813)
- Testing
- iGuide Intervention (Self-guided), iGuide 2 Intervention (Tailored/Targeted), Control
- Where
- United States
- Volunteers
- 313 people
- Sponsor
- Duke University
Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma
Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)
This phase Ib trial studies the side effects and best dose of niraparib when given together with radium Ra223 dichloride in treating subjects with prostate cancer that keeps growing even when the amount of testosterone in the…
- Conditions
- Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma, Hormone-refractory Prostate Cancer
- Trial name
- NCT03076203
- Testing
- Niraparib, Radium Ra 223 Dichloride
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Bladder Cancer, Triple Negative Breast Cancer
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This clinical trial is evaluating a drug called HMBD-001 (an anti-HER3 monoclonal antibody) in participants with advanced HER3 positive solid tumours.
- Conditions
- Bladder Cancer, Triple Negative Breast Cancer, Castration-resistant Prostate Cancer, Cervical Cancer
- Trial name
- NCT05057013
- Testing
- HMBD-001, HMBD-001 and enzalutamide
- Where
- 4 sites in United Kingdom
- Volunteers
- 81 people
- Sponsor
- Cancer Research UK
Carcinoma
A Non Interventional Study With Doce Onkovis (Docetaxel) Utilized for the Treatment of Cancer
The main purpose of this observational study with Docetaxel is to determine the number of treatment cycles and the quantity of Doce onkovis needed therefore under the special circumstance of ambulant chemotherapy.
- Trial name
- NCT01614002
- Where
- 23 sites in Germany
- Volunteers
- 371 people
- Sponsor
- Onkovis GmbH
Prostate Adenocarcinoma, Radiotherapy; Complications
Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy
Feasibility trial of twice high dose radiotherapy using Tomotherapy in patients with organ confined Prostate Cancer histologically proven.
- Conditions
- Prostate Adenocarcinoma, Radiotherapy; Complications, Tomotherapy
- Trial name
- THRIP (NCT03553212)
- Testing
- tomotherapy
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Prostate Adenocarcinoma
An Evaluation of Polymer Based Fiducials for Use in Imaging Patients Receiving Treatment for Prostate Cancer
This trial is to determine if prostate target delineation obtained through an ultrasound based system is equivalent in accuracy to the MRI image fusion, and if alignment correction vectors obtained from ultrasound imaging are of…
- Trial name
- Clarity (NCT01478412)
- Testing
- Polymer based fiducial placement
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- John Chang, MD
Advanced Cancer
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families.
- Trial name
- NCT02219711
- Testing
- MGCD516
- Where
- 43 sites in United States, South Korea
- Volunteers
- 193 people
- Sponsor
- Mirati Therapeutics Inc.
Cancer, Thyroid Cancer
Pharmaceutical Management in Targeted Radioligand Therapy
Targeted Radionuclide Therapy (TRT) is a treatment modality used in nuclear medicine to target cancer cells while preserving surrounding healthy tissues.
- Conditions
- Cancer, Thyroid Cancer, Metastatic Prostate Cancer, Neuroendocrine Tumor Carcinoid
- Trial name
- PharmTRT (NCT07389512)
- Where
- 3 sites in France
- Volunteers
- 600 people
- Sponsor
- Hospices Civils de Lyon
Prostate Cancer
A Study Evaluating Vaccination of Prostate Cancer Patients With Self Dendritic Cells Expressing MUC1
This study investigates the use of the patients own immune cells to treat prostate cancer. Cells are taken from the patient and grown in the laboratory to become specialized immune cells called dendritic cells.
- Trial name
- MUC1 (NCT00852007)
- Testing
- DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
Prostate Cancer
Biological Therapy in Treating Patients With Prostate Cancer
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a person's T cells in the laboratory and then reinfusing them may cause a stronger immune response and…
- Trial name
- NCT00039299
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
This phase I/II trial is studying the side effects and best dose of ixabepilone and mitoxantrone hydrochloride when given together with prednisone and to see how well they work in treating patients with metastatic prostate cancer…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT00331344
- Testing
- mitoxantrone hydrochloride, ixabepilone, prednisone
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Selenomethionine in Treating Patients Undergoing Surgery or Internal Radiation Therapy for Stage I or Stage II Prostate Cancer
RATIONALE: Selenomethionine may slow the growth of prostate cancer. Giving selenomethionine before surgery or internal radiation therapy may be an effective treatment for prostate cancer.
- Trial name
- NCT00736164
- Testing
- selenomethionine
- Sponsor
- Roswell Park Cancer Institute
Prostate Adenocarcinoma, Prostate Carcinoma
Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion
Prostate-specific membrane antigen (PSMA) agents have shown promise in detecting and treating prostate cancer. Gallium-68-labeled PSMA-11 (68Ga-PSMA-11) is a radioactive agent that binds to prostate cancer cells and can be imaged…
- Conditions
- Prostate Adenocarcinoma, Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- NCT04976257
- Testing
- Angiogram, Catheterization, Gallium Ga-labeled PSMA-11
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Ryan Kohlbrenner, MD